Research graph
References from Anticoagulation in cirrhosis: Indications, drug selection, and disease-modifying potential. Local targets link to admitted publications; unresolved targets remain external evidence.
Coagulopathy of chronic liver disease
2011 · External reference
Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity
10.1002/hep.21231 · 2006 · External reference
The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease
10.1111/jth.15239 · 2021 · External reference
Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nation-wide Cohort Study
10.1002/hep.32019 · 2021 · External reference
Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study
10.1038/ajg.2008.34 · 2009 · External reference
The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis
10.1160/th16-06-0450 · 2017 · External reference
Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis
10.1016/j.thromres.2022.05.004 · 2022 · External reference
Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis
10.1016/j.jhep.2023.02.023 · 2023 · External reference
Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis
10.1053/j.gastro.2012.07.018 · 2012 · External reference
Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study
10.1016/j.jhep.2025.06.035 · 2025 · External reference
Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH
10.1016/j.jtha.2024.05.023 · 2024 · External reference
DOACs in cirrhosis: Progress, pitfalls, and the path forward
10.1016/j.thromres.2026.109722 · 2026 · External reference
10.1016/j.rpth.2025.103296
10.1016/j.rpth.2025.103296 · External reference
Haemostasis in cirrhosis: Understanding destabilising factors during acute decompensation
10.1016/j.jhep.2023.01.010 · 2023 · External reference
Haemostatic Balance and Transfusion Strategies in Acute Liver Failure and Acute-On-Chronic Liver Failure: A Systematic Review
10.1111/liv.70378 · 2025 · External reference
Coagulation Failure in Patients With Acute-on-Chronic Liver Failure and Decompensated Cirrhosis: Beyond the International Normalized Ratio
10.1002/hep.30103 · 2018 · External reference
Evidence of normal thrombin generation in cirrhosis despite abnormal conventional coagulation tests
10.1002/hep.20569 · 2005 · External reference
Alterations in Primary Haemostasis in Patients With Liver Cirrhosis and Bacterial Infection
10.1111/liv.70649 · 2026 · External reference
Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: Guidance from the SSC of the ISTH
10.1111/jth.15562 · 2022 · External reference
Thrombin generation in patients with cirrhosis: the role of platelets
10.1002/hep.21266 · 2006 · External reference
Whole blood thrombin generation shows a significant hypocoagulable state in patients with decompensated cirrhosis
10.1016/j.jtha.2023.10.008 · 2024 · External reference
Evidence that low protein C contributes to the procoagulant imbalance in cirrhosis
10.1016/j.jhep.2013.03.036 · 2013 · External reference
Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD
10.1016/j.jhep.2021.12.038 · 2022 · External reference
Reticulated platelets are increased and hyper-activated in patients with cirrhosis, especially those with poor outcome
10.1016/j.dld.2024.03.007 · 2024 · External reference
High plasma levels of von Willebrand factor as a marker of endothelial perturbation in cirrhosis: relationship to endotoxemia
10.1002/hep.510230613 · 1996 · External reference
Total thrombus formation system exploration of primary hemostasis in cirrhotic patients
10.1016/j.rpth.2026.103370 · 2026 · External reference
The evolving knowledge on primary hemostasis in patients with cirrhosis: A comprehensive review
10.1097/hep.0000000000000349 · 2024 · External reference
Thrombin-activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis
10.1053/gast.2001.25481 · 2001 · External reference
Deficiency of thrombin activatable fibrinolysis inhibitor in cirrhosis is associated with increased plasma fibrinolysis
10.1053/jhep.2003.50277 · 2003 · External reference
Platelet protease nexin-1 limits fibrinolysis in patients with cirrhosis
2025 · External reference
Patients with cirrhosis have a disbalance between coagulation and fibrinolysis resulting in a prothrombotic phenotype
10.1016/j.jtha.2025.02.034 · 2025 · External reference
Fibrinogen dysfunction and fibrinolysis state in patients with hepatitis B-related cirrhosis
10.1080/16078454.2024.2392028 · 2024 · External reference
Procedural-Related Bleeding in Hospitalized Patients With Liver Disease (PROC-BLeeD): An International, Prospective, Multicenter Observational Study
10.1053/j.gastro.2023.05.046 · 2023 · External reference
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis
10.1016/j.jhep.2021.09.003 · 2022 · External reference
Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis
10.1016/j.jhep.2024.12.008 · 2025 · External reference
Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis)
1995 · External reference
Interruption of platelets and thrombin function as a new approach against liver fibrosis induced experimentally in rats
10.1016/j.lfs.2019.05.078 · 2019 · External reference
Inhibition of activated factor X; a new pathway in ameliorating carbon tetrachloride-induced liver fibrosis in rats
10.1002/jbt.22287 · 2019 · External reference
Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats
10.1016/j.jhep.2015.12.003 · 2016 · External reference
The anticoagulant rivaroxaban lowers portal hypertension in cirrhotic rats mainly by deactivating hepatic stellate cells
10.1002/hep.29084 · 2017 · External reference
Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis
10.1111/liv.13510 · 2018 · External reference
Mitigation of thromboinflammation by rivaroxaban ameliorates metabolic and structural manifestations of metabolic dysfunction-associated steatohepatitis in rats: Comparison to other antithrombotic drugs
10.1016/j.jpet.2025.103749 · 2025 · External reference
Mortality and Hepatic Decompensation in Patients With Cirrhosis and Atrial Fibrillation Treated With Anticoagulation
10.1002/hep.31264 · 2021 · External reference
Unresolved reference
External reference
Recompensation after acute decompensation in alcohol-related cirrhosis is rare and likely unrelated to platelet-poor plasma thrombin generation and fibrinolysis
10.1016/j.dld.2025.09.018 · 2026 · External reference
Increased thrombin generation is linked to first hepatic decompensation in patients with compensated cirrhosis
10.1097/hc9.0000000000001003 · 2026 · External reference
Epidemiology of portal vein thrombosis in liver cirrhosis: A systematic review and meta-analysis
10.1016/j.ejim.2022.05.032 · 2022 · External reference
Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study
10.1002/hep.27546 · 2015 · External reference
Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation
10.1136/gut.2004.042796 · 2005 · External reference
Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors
10.1016/j.jhep.2021.07.020 · 2021 · External reference
Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study
10.1111/liv.13500 · 2018 · External reference
Endothelial-to-mesenchymal transition: A targetable mechanism that contributes to portal vein thrombosis in cirrhosis
10.1097/hep.0000000000001547 · 2026 · External reference
Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies
10.1016/s2468-1253(24)00155-9 · 2024 · External reference
Baveno VIII - Advancing consensus in portal hypertension
2026 · External reference
Natural history of portal vein thrombosis in cirrhosis: A systematic review with meta-analysis
10.1111/jgh.16263 · 2023 · External reference
Unresolved reference
2026 · External reference
Nontumoral portal vein thrombosis in patients awaiting liver transplantation
10.1002/lt.24387 · 2016 · External reference
Meta-analysis and systematic review: Prevalence, graft failure, mortality, and post-operative thrombosis in liver transplant recipients with pre-operative portal vein thrombosis
10.1111/ctr.14520 · 2022 · External reference
Therapeutic anticoagulation after liver transplantation is not useful among patients with pre-transplant Yerdel-grade I/II portal vein thrombosis: A two-center retrospective study
10.1111/jth.15472 · 2021 · External reference
Portal vein thrombosis and liver transplant survival benefit
10.1002/lt.22105 · 2010 · External reference
Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis
10.1016/j.cgh.2012.01.012 · 2012 · External reference
Safety, Efficacy, and Long-Term Outcomes of Anticoagulation in Cirrhotic Portal Vein Thrombosis
10.1007/s10620-020-06695-4 · 2021 · External reference
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis
10.1038/s41395-018-0421-0 · 2019 · External reference
Efficacy and safety of anticoagulation in non-malignant portal vein thrombosis in patients with liver cirrhosis
10.1016/j.gastrohep.2018.06.005 · 2018 · External reference
Effects of Anticoagulants in Patients With Cirrhosis and Portal Vein Thrombosis: A Systematic Review and Meta-analysis
10.1053/j.gastro.2017.04.042 · 2017 · External reference
Role of nonneoplastic PVT in the natural history of patients with cirrhosis and first diagnosis of HCC
10.1097/hep.0000000000000538 · 2024 · External reference
Increased platelet ratio in patients with decompensated cirrhosis indicates a higher risk of portal vein thrombosis
10.1111/liv.15435 · 2023 · External reference
Is Post-TIPS Anticoagulation Therapy Necessary in Patients with Cirrhosis and Portal Vein Thrombosis? A Randomized Controlled Trial
10.1148/radiol.2015150369 · 2016 · External reference
Anticoagulation and Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis: A Prospective Observational Study
10.14309/ajg.0000000000001194 · 2021 · External reference
Feasibility, Safety and Efficacy of Transjugular Intrahepatic Portosystemic Shunt for the Management of Portal Vein Thrombosis in Cirrhosis
10.1016/j.jceh.2025.102580 · 2025 · External reference
Cirrhosis is Associated with an Increased 30-Day Mortality After Venous Thromboembolism
10.1038/ctg.2015.27 · 2015 · External reference
Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis
10.1038/s41424-018-0002-y · 2018 · External reference
Thromboprophylaxis for venous thromboembolism prevention in hospitalized patients with cirrhosis: Guidance from the SSC of the ISTH
10.1111/jth.15829 · 2022 · External reference
Safety and efficacy of venous thromboembolism prophylaxis in patients with cirrhosis: A systematic review and meta-analysis
10.1111/liv.15609 · 2023 · External reference
Outcome of pharmacological thromboprophylaxis in hospitalized patients with cirrhosis - a systematic review and meta-analysis
10.1097/meg.0000000000002564 · 2023 · External reference
Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding
10.1111/liv.12211 · 2014 · External reference
2026 AHA/ACC/ACCP/ACEP/CHEST/SCAI/SHM/SIR/SVM/SVN Guideline for the Evaluation and Management of Acute Pulmonary Embolism in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
10.1016/j.jacc.2025.11.005 · 2026 · External reference
Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: a meta-analysis
10.1097/meg.0000000000001315 · 2019 · External reference
Cirrhotic cardiomyopathy
10.1016/j.jhep.2018.01.006 · 2018 · External reference
Cirrhotic cardiomyopathy
10.3390/gastroent12010008 · 2021 · External reference
2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)
10.1093/eurheartj/ehae176 · 2024 · External reference
Anticoagulation in patients with atrial fibrillation and liver cirrhosis
2022 · External reference
Atrial fibrillation, liver cirrhosis, thrombosis, and bleeding: A Danish population-based cohort study
10.1002/rth2.12668 · 2022 · External reference
Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation
10.1161/jaha.118.011112 · 2019 · External reference
Efficacy and Safety of Direct Oral Anticoagulants Compared to Vitamin K Antagonists for Atrial Fibrillation in Patients With Liver Cirrhosis: An Update Systematic Review and Meta-analysis
10.1016/j.jceh.2025.102534 · 2025 · External reference
Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation: The ALONE-AF Randomized Clinical Trial
10.1001/jama.2025.14679 · 2025 · External reference
Left atrial appendage closure device outcomes among cirrhosis patients with atrial fibrillation: a United States National Cohort Study
10.1093/europace/euad004 · 2023 · External reference
Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis
10.1111/liv.13285 · 2017 · External reference
AGA Clinical Practice Update on Management of Portal Vein Thrombosis in Patients With Cirrhosis: Expert Review
10.1053/j.gastro.2024.10.038 · 2025 · External reference
Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases
10.1002/hep.31646 · 2021 · External reference
ACG Clinical Guideline: Disorders of the Hepatic and Mesenteric Circulation
10.14309/ajg.0000000000000486 · 2020 · External reference
Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis
10.1097/mcg.0b013e3181b3ab44 · 2010 · External reference
Comparison of Fondaparinux and Low-Molecular-Weight Heparin in the Treatment of Portal Vein Thrombosis in Cirrhosis
10.1016/j.amjmed.2021.05.013 · 2021 · External reference
Fondaparinux is effective for acute portal vein thrombosis in decompensated cirrhotic patients
10.1097/md.0000000000008256 · 2017 · External reference
Comparison of Apixaban, Rivaroxaban, Dabigatran, and Vitamin K Antagonists in Patients With Atrial Fibrillation and Liver Disease: A Network Meta-Analysis
2024 · External reference
Efficacy and safety of direct oral anticoagulants versus traditional anticoagulants in cirrhotic patients with venous thromboembolism and atrial fibrillation: a systematic review and meta-analysis
10.1080/00365521.2026.2672441 · 2026 · External reference
Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis
10.1055/s-0043-1770100 · 2023 · External reference
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis
10.1007/s11239-021-02424-4 · 2021 · External reference
Direct oral anticoagulants and advanced liver disease: A systematic review and meta-analysis
10.1111/eci.13397 · 2021 · External reference
Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants
10.1016/j.ijcard.2018.01.097 · 2018 · External reference
Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation: A Nationwide Cohort Study
10.7326/m23-3067 · 2024 · External reference
Comparative Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin in Patients With Atrial Fibrillation and Chronic Liver Disease: A Nationwide Cohort Study
10.1161/circulationaha.122.060687 · 2023 · External reference
Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study
10.1016/j.thromres.2024.03.024 · 2024 · External reference
Direct Oral Anticoagulant Type and Dose in Atrial Fibrillation With Decompensated Cirrhosis: A Propensity-Matched Analysis
10.1016/j.gastha.2026.100996 · 2026 · External reference
Assessment of the efficiency and safety of anti-coagulation therapy in patients with liver cirrhosis and atrial fibrillation
10.5114/ceh.2023.130605 · 2023 · External reference
Edoxaban Versus Warfarin in Patients With Atrial Fibrillation and History of Liver Disease
10.1016/j.jacc.2019.04.061 · 2019 · External reference
Comparative outcomes of direct oral anticoagulants versus warfarin in patients with atrial fibrillation and liver cirrhosis: A propensity score matched TriNetX analysis
10.1007/s11239-026-03359-4 · 2026 · External reference
Comparison of the efficacy and safety between rivaroxaban and dabigatran in the treatment of acute portal vein thrombosis in cirrhosis
10.1186/s12876-023-02960-8 · 2023 · External reference
Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival
10.1111/apt.18474 · 2025 · External reference
Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis
10.1111/hepr.12895 · 2018 · External reference
Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis
10.1038/s41598-024-60235-y · 2024 · External reference
Evaluation of the efficacy and safety of direct oral anticoagulants in the treatment of portal vein thrombosis
10.1097/meg.0000000000001958 · 2021 · External reference
Direct oral anticoagulants in portal vein thrombosis in patients with cirrhosis: a systematic review and meta-analysis
10.1182/bloodadvances.2026019823 · 2026 · External reference
Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: A systematic review and meta-analysis
10.1016/j.dld.2021.07.039 · 2022 · External reference
Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment
10.1007/s40268-021-00359-y · 2021 · External reference
Pharmacokinetic robustness of direct oral anticoagulants vs. phenprocoumon in the emergency setting: impact of renal and hepatic impairment
10.1016/j.ejim.2026.107030 · 2026 · External reference
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor
10.1111/bcp.12054 · 2013 · External reference
An open-label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics
10.1002/jcph.550 · 2015 · External reference
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on vascular diseases of the liver
10.1016/j.jhep.2025.08.001 · 2026 · External reference
Unresolved reference
External reference
Main Lessons of the Recent Andexanet Withdrawal
10.1159/000551185 · 2026 · External reference
Safety of direct oral anticoagulants in patients with advanced liver disease
10.1111/liv.14992 · 2021 · External reference
Rates of Bleeding and Discontinuation of Direct Oral Anticoagulants in Patients With Decompensated Cirrhosis
10.1016/j.cgh.2020.08.007 · 2021 · External reference
A major research gap: The use of anticoagulants in cirrhosis
10.1016/j.jhep.2023.06.001 · 2023 · External reference
Unresolved reference
External reference
Continuous versus intermittent anticoagulation during endoscopic treatment of esophageal varices in cirrhosis: a randomized controlled trial
10.1177/17562848261439217 · 2026 · External reference
